Study on the Mechanism of CCKBR-dependent Long-term Potentiation and Identification of a Biased CCKBR Agonist that Blocks the Potentiation in a β-arrestin Dependent Manner

Student thesis: Doctoral Thesis

Abstract

G protein-coupled receptors (GPCRs) transmit signaling through diversified downstream pathways involving distinctive biological mechanisms and assorted disease-related effects. CCKBR, as a GPCR, its activation induces neocortex long-term potentiation (LTP) of excitatory transmission and enhances memory formation, while its antagonists weaken the LTP in the amygdala and are used to alleviate depression-like behaviours in mice. However, the mechanism of CCKBR dependent-LTP (CCKBR-LTP) remains elusive. There is also no highly signaling pathway-biased and CCKBR-selective agonist to modulate the CCKBR-LTP. Here, we discovered a β-arrestin biased and CCKBR selective agonist with IC50 = 15.3nM, and we named the agonist 5R15. Full activation of the β-arrestin signaling pathway with 5R15 couldn’t induce the auditory cortex (AC) CCKBR-LTP in the mouse brain slice but efficiently induced the endocytosis of CCKBR in cell-based assays. Further Multi-Electrode Array (MEA) results demonstrated that the CCKBR-LTP was dependent on Gαq/11-Ca2+ and Gαs-cAMP signaling pathways. Both these two signaling pathways induced by CCKBR activation were suppressed by 5R15 with high potency, suggesting that this agonist could be an antagonist for the CCKBR-LTP. Accordingly, the LTP was completely blocked by 5R15 at a low concentration in a β-arrestin dependent manner. The blockade was abolished by mutating the key site Asn353, which determines the β-arrestin signaling bias induced by 5R15. These results revealed the signal pathway preference of the CCKBR-LTP in the AC and BLA and identified a novel “antagonist” of the LTP, which provides us with broader insights into developing new drugs targeting CCKBR. The concept that β-arrestin-biased agonists could function as antagonists for other signaling pathways might be extended to the development of other GPCR drugs.
Date of Award23 Dec 2024
Original languageEnglish
Awarding Institution
  • City University of Hong Kong
SupervisorJufang HE (Supervisor)

Cite this

'